Header

UZH-Logo

Maintenance Infos

Urinary biomarkers for prostate cancer


Giunchi, Francesca; Ciccarese, Chiara; Montironi, Rodolfo; Scarpelli, Marina; Lopez-Beltran, Antonio; Cheng, Liang; Moch, Holger; Massari, Francesco; Fiorentino, Michelangelo (2017). Urinary biomarkers for prostate cancer. Current Drug Metabolism, 18:Epub ahead of print.

Abstract

Urine may represent a convenient source of biomarkers for the early detection of prostate cancer (PCa) since contains secreted prostatic products and exfoliated tumor cells. Furthermore urine are easy to collect with non-invasive procedures and they are repeatable. Several urinary biomarkers for PCa have been proposed in the past but only one (PCA3) has been approved for clinical use and even this is not widely utilized in the routine practice. Most of these, particularly the proteins, were abandoned due to lack of confirmation. DNA markers have been proposed but they result less suitable compared to other malignancies such as bladder cancer due to the limited amount of DNA somatic alterations in PCa compared to gene fusions and pathway activations. RNA biomarkers are still the most promising and particularly miRNA and AMACR mRNA but the main weaknesses that prevented the full clinical implementation are the absence of a validated of the cut-off levels and the identification of consistent reference standards.

Abstract

Urine may represent a convenient source of biomarkers for the early detection of prostate cancer (PCa) since contains secreted prostatic products and exfoliated tumor cells. Furthermore urine are easy to collect with non-invasive procedures and they are repeatable. Several urinary biomarkers for PCa have been proposed in the past but only one (PCA3) has been approved for clinical use and even this is not widely utilized in the routine practice. Most of these, particularly the proteins, were abandoned due to lack of confirmation. DNA markers have been proposed but they result less suitable compared to other malignancies such as bladder cancer due to the limited amount of DNA somatic alterations in PCa compared to gene fusions and pathway activations. RNA biomarkers are still the most promising and particularly miRNA and AMACR mRNA but the main weaknesses that prevented the full clinical implementation are the absence of a validated of the cut-off levels and the identification of consistent reference standards.

Statistics

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Pathology and Molecular Pathology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:18 May 2017
Deposited On:13 Jun 2017 12:46
Last Modified:14 Jun 2017 01:03
Publisher:Bentham Science Publishers Ltd.
ISSN:1389-2002
Publisher DOI:https://doi.org/10.2174/1389200218666170518161140
PubMed ID:28524004

Download

Full text not available from this repository.
View at publisher